TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

MEGESTROL ACETATE

MEGESTROL ACETATE
Metabolic Approved 1988-08-08
12
Indications
--
Phase 3 Trials
37
Years on Market

Details

Status
Prescription
First Approved
1988-08-08
Routes
ORAL
Dosage Forms
SUSPENSION, TABLET

MEGESTROL ACETATE Approval History

Loading approval history...

What MEGESTROL ACETATE Treats

4 indications

MEGESTROL ACETATE is approved for 4 conditions since its original approval in 1988. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Anorexia
  • Cachexia
  • Weight Loss
  • Acquired Immunodeficiency Syndrome
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

MEGESTROL ACETATE FDA Label Details

Pro

Indications & Usage

Megestrol acetate oral suspension, USP is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS).

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.